BamSEC and AlphaSense Join Forces
Learn More

IDEAYA Biosciences Inc. – Material Contracts

NASDAQ: IDYA    
Share price (6/29/26): $36.55    
Market cap (6/29/26): $3.211 billion

Material Contracts Filter

EX-10.3
from 10-Q 22 pages Second Amendment to Lease 5000 Shoreline Court
12/34/56
EX-10.2
from 10-Q 21 pages IDEAYA Biosciences, Inc. Employment Agreement
12/34/56
EX-10.1
from 10-Q 21 pages IDEAYA Biosciences, Inc. Employment Agreement
12/34/56
EX-10.15
from 10-K 4 pages IDEAYA Biosciences, Inc. Non-Employee Director Compensation Program Amended Effective as of June 23, 2025
12/34/56
EX-10.1
from 10-Q 83 pages License Agreement Article 1 Definitions
12/34/56
EX-10.3
from 10-Q 2 pages Amendment to the IDEAYA Biosciences, Inc. 2023 Employment Inducement Award Plan * * *
12/34/56
EX-10.2
from 10-Q 15 pages IDEAYA Biosciences, Inc. Employment Agreement
12/34/56
EX-10.1
from 10-Q 4 pages IDEAYA Biosciences, Inc. Non-Employee Director Compensation Program Amended Effective as of June 23, 2025
12/34/56
EX-10.4
from 10-Q 70 pages Clinical Study Collaboration and Supply Agreement
12/34/56
EX-10.3
from 10-Q 9 pages IDEAYA Biosciences, Inc. Employment Agreement Addendum
12/34/56
EX-10.2
from 10-Q 21 pages IDEAYA Biosciences, Inc. Employment Agreement
12/34/56
EX-10.1
from 10-Q 4 pages IDEAYA Biosciences, Inc. Non-Employee Director Compensation Program Amended Effective as of January 1, 2025
12/34/56
EX-10.25(B)
from 10-K 15 pages First Amendment to Lease 5000 Shoreline Court
12/34/56
EX-10.20(F)
from 10-K 6 pages Amendment No. 5 to Agreement
12/34/56
EX-10.19(B)
from 10-K 5 pages Amendment Number One to Option and License Agreement
12/34/56
EX-10.27
from 10-K 63 pages License Agreement
12/34/56
EX-10.12
from 10-K 22 pages IDEAYA Biosciences, Inc. Employment Agreement
12/34/56
EX-10.2
from 10-Q 18 pages IDEAYA Biosciences, Inc. Employment Agreement This Employment Agreement (The “Agreement”) Is Entered Into Between IDEAYA Biosciences, Inc., a Delaware Corporation (The “Company”) and Doug Snyder (“Executive” And, Together With the Company, the “Parties”) Effective as of September 18, 2024 (The “Effective Date”). Whereas, the Company Desires to Assure Itself of the Services of Executive by Engaging Executive to Perform Services as an Employee of the Company Under the Terms Hereof; and Whereas, Executive Desires to Provide Services to the Company on the Terms Herein Provided Effective as of the Effective Date. Now, Therefore, in Consideration of the Foregoing, and for Other Good and Valuable Consideration, Including the Respective Covenants and Agreements Set Forth Below, the Receipt and Sufficiency of Which Are Hereby Acknowledged, the Parties Hereto Agree as Follows: 1. Employment. (A) General. the Company Shall Employ Executive Upon the Terms and Conditions Provided Herein Effective as of the Effective Date
12/34/56
EX-10.1
from 10-Q 59 pages Option and License Agreement
12/34/56
EX-10.1
from 10-Q 56 pages Clinical Trial Collaboration and Supply Agreement
12/34/56